Updates are available Correction dated 2024-10-18
Click to view Correction: https://doi.org/10.1007/s13555-024-01285-y
-
Authors
Chajra, Hanane https://orcid.org/0000-0001-6751-6659
Saguet, Thibaut https://orcid.org/0000-0003-1274-1773
Granger, Corinne https://orcid.org/0000-0001-5117-448X
Breton, Lionel https://orcid.org/0009-0003-4912-3263
Pinto, Pedro Contreiras https://orcid.org/0000-0002-5723-0750
Machicoane, Mickael https://orcid.org/0009-0002-2666-1520
Le Doussal, Jean Marc
- License Information
-
More Information
Article History
Received: 16 July 2024
Accepted: 4 September 2024
First Online: 19 September 2024
Change Date: 18 October 2024
Change Type: Correction
Change Details: A Correction to this paper has been published:
Change Details: https://doi.org/10.1007/s13555-024-01285-y
Declarations
:
: Hanane Chajra, Mickael Machicoane, Thibaut Saguet, and Jean-Marc Le Doussal are employees of ACTIVEN, the manufacturer of the active ingredient under study. Corinne Granger and Lionel Breton act as consultants to ACTIVEN. Pedro Contreiras Pinto is the investigator of the clinical study.
: The clinical study protocol was approved on 8 April 2022 by the Independent Ethics Committee of Clinic Dr Carlos Ramos, Lousado, Portugal. The study was conducted following Good Clinical Practice Guidelines and general principles of Law 46/2004 of August 19th. Prior written informed consent was obtained from all subjects, and the study was performed following the Declaration of Helsinki (1964) and its subsequent amendments and COLIPA guidelines for the Evaluation of the Efficacy of Cosmetic Products.
